Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

EU and US take steps to battle coronavirus mutations

By Brian Buntz | February 19, 2021

SARS-CoV-2

Electron microscopic image from the first confirmed case of SARS-CoV-2 in the U.S. Image from CDC.

The EU recently added clauses to COVID-19 vaccine contracts to prioritize vaccines that are effective against emerging SARS-CoV-2 variants.

Meanwhile, a U.S. House bill that would provide $1.75 billion for genomic sequencing of coronavirus samples is scheduled for floor debate and the Senate is considering similar legislation.

The UK variant (B.1.1.7) that is spreading across Europe and the U.S. is more infectious and possibly more dangerous than earlier strains and could become dominant in the U.S. by March, according to CDC projections. Even more potentially threatening are the South Africa (B.1.351) and Brazil (P.1) variants, which are also spreading in both regions.

The U.K. helped the world understand the threat of B.1.1.7 with its sizable genomic sequencing apparatus. The country has sequenced roughly 10% of coronavirus samples it has collected. As of January, the U.S. had sequenced approximately 0.32% of total cases, according to The Washington Post. Other estimates put the total closer to 0.5% of SARS-CoV-2 samples.

The House bill also would enable the development of a national network to track the genetic mutations of SARS-CoV-2. The Senate known a the Tracking COVID-19 Variants Act would provide $2 billion for genome sequencing. Introduced by Sen. Tammy Baldwin (D-Wis.), that bill also would require the U.S. to sequence at least 15% of positive SARS-CoV-2 samples.

“Variants represent a growing threat to the health and security of our nation, and right now the U.S. is lagging behind other countries in tracking new and emerging variants of this deadly virus,” Sen. Baldwin said in a press release. The U.S. should aim to be a global leader in genomic testing of SARS-CoV-2 samples, she stressed. “I’m glad to see this legislation move forward today so we can better identify, survey and understand these variants, and better protect all Americans from this public health crisis,” Baldwin concluded.

 

 

 

 

 

 


Filed Under: Genomics/Proteomics, Infectious Disease
Tagged With: B.1.1.7, B.1.351, coronavirus, coronavirus mutations, covid-19, COVID-19 vaccine, COVID-19 vaccine trial, P.1, SARS-CoV-2, U.K. variant
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Pfizer
Pfizer shares positive top-line data from Phase 3 Study of pneumococcal vaccine
Vaccine
The most common monkeypox vaccine side effects
FDA logo
FDA grants emergency use authorization to Jynneos monkeypox vaccine to support ‘dose sparing’
JYNNEOS vaccine
Jynneos vaccine: The best weapon against monkeypox?

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50